Skip to main content
Premium Trial:

Request an Annual Quote

DermTech Raises $2.4M

NEW YORK(GenomeWeb) – Melanoma test development firm DermTech has raised $2.4 million. 

DermTech disclosed the financing in a document filed with the US Securities and Exchange Commission earlier this week. In an email, DermTech CFO and Treasurer Steven Kemper told GenomeWeb that participants in the private financing round included existing investors. He added that the La Jolla, Calif.-based firm is launching its pigmented lesion assay and is currently testing the assay with certain US dermatologists with plans for a broader launch in the second half of this year. 

DermTech filed with the SEC to go public last spring but shelved those plans in November. The firm develops gene expression tests for diagnosing skin conditions, including skin cancer, inflammatory diseases, and age-related conditions. Its technology uses an "adhesive patch biopsy" that provides a tissue sample non-invasively.

The Scan

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.

Australian Survey Points to Public Support for Genetic Risk Disclosure in Relatives of At-Risk Individuals

A survey in the European Journal of Human Genetics suggests most adult Australians are in favor of finding out if a relative tests positive for a medically actionable genetic variant.

Study Links Evolution of Stony Coral Skeleton to Bicarbonate Transporter Gene

A PNAS paper focuses on a skeleton-related bicarbonate transporter gene introduced to stony coral ancestors by tandem duplication.

Hormone-Based Gene Therapy to Sterilize Domestic Cat

A new paper in Nature Communication suggests that gene therapy could be a safer alternative to spaying domestic cats.